疫苗的研发已经有数十年,但是没有疫苗上市。[[辉瑞]]、[[葛兰素史克]]和[[莫德纳]]正在积极研发疫苗<ref name=biopharmadive>{{Cite web|title=Jonathan Gardner, Pfizer's fast progress shines spotlight on an emerging vaccine race, July 30, 2021|url=https://www.biopharmadive.com/news/pfizers-fast-progress-shines-spotlight-on-an-emerging-vaccine-race/604220|access-date=2021-08-04|archive-date=2021-08-04|archive-url=https://web.archive.org/web/20210804001135/https://www.biopharmadive.com/news/pfizers-fast-progress-shines-spotlight-on-an-emerging-vaccine-race/604220/}}</ref>。辉瑞(Pfizer)公司2021年7月底宣布计划在两个月内开始对成人[[呼吸道合胞病毒疫苗]]进行3期试验,并于2022年初完成<ref name=biopharmadive/>。2021年8月,[[莫德纳]]的人类[[呼吸道合胞病毒疫苗]] (mRNA-1345)获得[[美国食品药品监督管理局]])(FDA){{link-en|快速通道指定|Fast track (FDA)}} <ref>{{Cite web|title=Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345), BUSINESS WIRE, August 3 2021|url=https://www.businesswire.com/news/home/20210803005702/en/Moderna-Receives-FDA-Fast-Track-Designation-for-Respiratory-Syncytial-Virus-RSV-Vaccine-mRNA-1345|access-date=2021-08-03|archive-date=2021-08-04|archive-url=https://web.archive.org/web/20210804215651/https://www.businesswire.com/news/home/20210803005702/en/Moderna-Receives-FDA-Fast-Track-Designation-for-Respiratory-Syncytial-Virus-RSV-Vaccine-mRNA-1345}}</ref>。
疫苗的研发已经有数十年,但是没有疫苗上市。[[辉瑞]]、[[葛兰素史克]]和[[莫德纳]]正在积极研发疫苗<ref name=biopharmadive>{{Cite web|title=Jonathan Gardner, Pfizer's fast progress shines spotlight on an emerging vaccine race, July 30, 2021|url=https://www.biopharmadive.com/news/pfizers-fast-progress-shines-spotlight-on-an-emerging-vaccine-race/604220|access-date=2021-08-04|archive-date=2021-08-04|archive-url=https://web.archive.org/web/20210804001135/https://www.biopharmadive.com/news/pfizers-fast-progress-shines-spotlight-on-an-emerging-vaccine-race/604220/}}</ref>。辉瑞(Pfizer)公司2021年7月底宣布计划在两个月内开始对成人[[呼吸道合胞病毒疫苗]]进行3期试验,并于2022年初完成<ref name=biopharmadive/>。2021年8月,[[莫德纳]]的人类[[呼吸道合胞病毒疫苗]](mRNA-1345)获得[[美国食品药品监督管理局]])(FDA){{link-en|快速通道指定|Fast track (FDA)}} <ref>{{Cite web|title=Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345), BUSINESS WIRE, August 3 2021|url=https://www.businesswire.com/news/home/20210803005702/en/Moderna-Receives-FDA-Fast-Track-Designation-for-Respiratory-Syncytial-Virus-RSV-Vaccine-mRNA-1345|access-date=2021-08-03|archive-date=2021-08-04|archive-url=https://web.archive.org/web/20210804215651/https://www.businesswire.com/news/home/20210803005702/en/Moderna-Receives-FDA-Fast-Track-Designation-for-Respiratory-Syncytial-Virus-RSV-Vaccine-mRNA-1345}}</ref>。